,,ii #aai? ,,congress #b;d ,session ,s4 #ebfe ,,9 ,,! ,,s5ate ,,( ,,! ,,unit$ ,,/ates ,augu/ #e1 #bjbf,mr4 ,%eehy 7= himself1 ,mr4 ,mc,cormick1 & ,mr4 ,budd7 introduc$ ! foll[+ bill2 :i* 0 read twice & ref]r$ to ! ,committee on ,f9ance ,a ,,bill ,to id5tify & take action aga9/ int]national trade practices ( high income c\ntries t unfairly exploit innovation by deviat+ f m>ket-bas$ policies & unfairly exploit ,unit$ ,/ates innovation1 & = o!r purposes4 #a4 ,%ort title ,?is ,act may be cit$ z ! ,use ,sov]eignty ,to r$uce ,rx ,act or ! ,u,s,t,rx ,act4 #b4 ,f9d+s2 s5se ( ,congress 7a7 ,f9d+s ,congress f9ds ! foll[+3 7#a7 ,ph>maceutical price controls 9 =eign m>kets di/ort global trade fl[s & competition by depress+ ! prices ( innovative drugs & exploit+ ph>maceutical innovations rese>*$ & develop$ 9 ! ,unit$ ,/ates4 7#b7 ,by sett+ prices at levels t are n m>ket-bas$1 su* price controls und]value ! discov]y ( new1 innovative treatm5ts1 dim9i% opportunities & inc5tives = global innovation 9 new m$ic9es1 & ?reat5 to re/rict access to new treatm5ts & cures = ,unit$ ,/ates pati5ts & consum]s4 7#c7 ,recogniz+ ^? dynamics1 x is critical t ! ,unit$ ,/ates use all available trade tools to address su* free-rid+ to ensure t =eign gov]nm5t regulatory reimbursem5t regimes are transp>5t1 provide proc$ural fairness1 are non-discrim9atory1 & provide full m>ket access to ,unit$ ,/ates products4 7b7 ,s5se ( ,congress ,x is ! s5se ( ,congress t-- 7#a7 ensur+ ! security ( innovative & af=dable heal?c>e is a top priority = ! p ( ! ,unit$ ,/ates & = ,congress2 7#b7 =eign gov]nm5t policies t m&ate artificially l[ drug prices 9 =eign m>kets und]m9e t priority by r$uc+ global inc5tives to inve/ 9 ! developm5t ( new m$ic9es2 7#c7 su* exploitative behavior unfairly %ifts ! co/ ( develop+ new treatm5ts to ! ,unit$ ,/ates & unduly relies on ,unit$ ,/ates pati5ts & taxpay]s to f9ance global ph>maceutical innovation2 & 7#d7 safegu>d+ access to life-sav+ treatm5ts = ,unit$ ,/ates pati5ts requires combat+ su* behavior s t =eign c\ntries pay _! fair %>e ( ! co/s associat$ ) ! developm5t ( new drugs4 #c4 ,*ief ,ph>maceutical ,trade ,negotiator ,section #ada ( ! ,trade ,act ( #aigd 7#ai ,u4,s4,c4 #baga7 is am5d$-- 7#a7 9 subsection 7b77#b7-- 7,a7 9 ! fir/ s5t5ce1 by ins]t+ "o ,*ief ,ph>maceutical ,trade ,negotiator1 aft] "o ,*ief ,agricultural ,negotiator12 & 7,b7 by ins]t+ ! ,*ief ,ph>maceutical ,trade ,negotiator1 aft] ! ,*ief ,agricultural ,negotiator1 ea* place x appe>s2 & 7#b7 9 subsection 7c71 by add+ at ! end ! foll[+ new p>agraph3 7#g7 ,! pr9cipal functions ( ! ,*ief ,ph>maceutical ,trade ,negotiator %all be to conduct trade negotiations1 en=ce trade agreem5ts relat+ to ,unit$ ,/ates ph>maceutical products1 & take appropriate action to address acts1 policies1 or practices ( high-income c\ntries t h a significant adv]se impact on ! ability ( ,unit$ ,/ates ph>maceutical manufactur]s to enjoy full m>ket access4 ,! ,*ief ,ph>maceutical ,trade ,negotiator %all be a vigor\s advocate on behalf ( ,unit$ ,/ates manufactur]s & consum]s ( ph>maceutical products & %all p]=m su* o!r functions z ! ,unit$ ,/ates ,trade ,repres5tative may direct4 ,9 c>ry+ out su* duties1 ! ,*ief ,ph>maceutical ,negotiator %all1 z appropriate1 consult or coord9ate ) ! ,*ief ,intellectual ,prop]ty ,negotiator4 4 #d4 ,annual report on acts1 policies1 & practices ( high income c\ntries 7a7 ,li/ ( high income c\ntries ,! ,unit$ ,/ates ,trade ,repres5tative %all compile & annually update a li/ ( ea* =eign c\ntry t is def9$ z high income by ! (ficial /ati/ics ( ! ,int]national ,bank = ,recon/ruction & ,developm5t ( ! ,_w ,bank4 7b7 ,report requir$ ,) respect to ea* c\ntry includ$ on ! mo/ rec5t li/ requir$ "u subsection 7a71 ! ,unit$ ,/ates ,trade ,repres5tative1 act+ ?r\gh ! ,*ief ,ph>maceutical ,trade ,negotiator 7z e/abli%$ pursuant to ! am5dm5ts made by section #c71 %all annually submit to ! ,committee on ,ways & ,means ( ! ,h\se ( ,repres5tatives & ! ,committee on ,f9ance ( ! ,s5ate & concurr5tly publi% on a publicly available website ( ! ,unit$ ,/ates ,trade ,repres5tative a report t-- 7#a7 describes 9 detail ! results ( a review ( ! acts1 policies1 & practices ( su* c\ntry relat+ to ! trade 9 ph>maceutical products 9 ! previ\s fiscal ye>2 7#b7 det]m9es :e!r su* acts1 policies1 or practices-- 7,a7 are n develop$ & implem5t$ 9 a fair1 nondiscrim9atory1 & transp>5t mann]2 7,b7 are n m>ket-bas$ or d n appropriately recognize ! value ( innovative m$ic9es2 7,c7 d5y reciprocal m>ket access = ,unit$ ,/ates products2 7,d7 dim9i% inc5tives = innovation 9 a mann] t delays1 prev5ts1 or o!rwise adv]sely impacts ! introduction ( new m$ic9es 9 ! ,unit$ ,/ates2 7,e7 violate or are inconsi/5t ) ! provisions (1 or o!rwise d5y b5efits to ! ,unit$ ,/ates "u1 any bilat]al or multilat]al trade agreem5t ) su* c\ntry2 & 7,f7 are unju/ifiable or impose a significant burd5 or unreasonable or discrim9atory re/riction on ,unit$ ,/ates comm]ce ) su* c\ntry2 & 7#c7 describes ! curr5t /atus ( any responsive actions tak5 by ! ,unit$ ,/ates ) respect to acts1 policies1 or practices = :i* ! ,unit$ ,/ates ,trade ,repres5tative has det]m9$ & includ$ 9 any prior report1 pursuant to p>agraph 7#b71 t ! int]e/s ( ! ,unit$ ,/ates are h>m$1 includ+ responsive actions pursuant to title ,,iii ( ! ,trade ,act ( #aigd 7#ai ,u4,s4,c4 #bdaa et seq474 #e4 ,response to adv]se actions by high income c\ntries ,n lat] ?an #cj days aft] ! ,unit$ ,/ates ,trade ,repres5tative det]m9es t an act1 policy1 or practice ( a c\ntry includ$ 9 ! mo/ rec5t li/ requir$ "u section #d7;a7 meets any ( ! crit]ia describ$ 9 section #d7;b77#b71 ! ,unit$ ,/ates ,trade ,repres5tative %all submit to ,committee on ,ways & ,means ( ! ,h\se ( ,repres5tatives & ! ,committee on ,f9ance ( ! ,s5ate a plan to respond to ! act1 policy1 or practice1 :i* may include initiat+ an inve/igation "u title ,,iii ( ! ,trade ,act ( #aigd 7#ai ,u4,s4,c4 #bdaa et seq471 9 accordance ) section #cjb7;b77#a7 ( t ,act4